BPTH Logo

Bio-Path Holdings, Inc. (BPTH) 

NASDAQ
Market Cap
$2.85M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
582 of 963
Rank in Industry
316 of 552

Largest Insider Buys in Sector

BPTH Stock Price History Chart

BPTH Stock Performance

About Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Insider Activity of Bio-Path Holdings, Inc.

Over the last 12 months, insiders at Bio-Path Holdings, Inc. have bought $0 and sold $0 worth of Bio-Path Holdings, Inc. stock.

On average, over the past 5 years, insiders at Bio-Path Holdings, Inc. have bought $0 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 7,343 shares for transaction amount of $8,958 was made by Garrison Michael J. (director) on 2015‑07‑13.

List of Insider Buy and Sell Transactions, Bio-Path Holdings, Inc.

2019-01-18Sale10 percent owner
64,457
5.7695%
$2.66$171,643+381.85%
2015-07-13Purchasedirector
7,343
0.0076%
$1.22$8,958+13.64%
2015-07-09Purchasedirector
8,724
0.0097%
$1.17$10,207+27.35%
2015-07-08Purchasedirector
21,015
0.0244%
$1.20$25,218+29.57%
2015-07-07Purchasedirector
38,985
0.0424%
$1.18$46,006+23.14%
2013-06-12Purchasedirector
340,000
0.2889%
$0.30$102,000+376.42%
2009-12-02Purchasedirector
350,000
0.4559%
$0.25$87,500-11.11%
2009-10-13Purchasedirector
400,000
0.6337%
$0.25$100,000+10.81%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.